Literature DB >> 34721508

The Prognostic Impact of Tumor Differentiation on Recurrence and Survival after Resection of Hepatocellular Carcinoma Is Dependent on Tumor Size.

Hiroji Shinkawa1, Shogo Tanaka1, Daijiro Kabata2, Shigekazu Takemura1, Ryosuke Amano1, Kenjiro Kimura1, Masahiko Kinoshita1, Shoji Kubo1.   

Abstract

INTRODUCTION: The present study aimed to evaluate the effect of poor differentiation and tumor size on survival outcome after hepatic resection of hepatocellular carcinoma (HCC).
METHODS: A total of 1,107 patients who underwent initial and curative hepatic resection for HCC without macroscopic vascular invasion participated in the study. Using the multivariable Cox proportional hazards regression model, we evaluated changes in hazard ratios (HRs) for the association between tumor differentiation and survival based on tumor size.
RESULTS: In patients with poorly (Por) differentiated HCCs, the adjusted HRs of reduced overall survival (OS), recurrence-free survival (RFS), early RFS, and early extrahepatic RFS were 1.31 (95% confidence interval [CI]; 1.07-1.59), 1.07 (95% CI 0.89-1.28), 1.31 (95% CI 1.06-1.62), and 1.81 (95% CI 1.03-3.17), respectively. Moreover, based on an analysis of the effect modification of tumor differentiation according to tumor size, Por HCC was found to be associated with a reduced OS (p = 0.033). The HRs of Por HCCs sharply increased in patients with tumors measuring up to 5 cm. The adjusted HRs of reduced OS in patients with Por HCCs measuring <2, ≥2 and <5, and ≥5 cm were 1.22 (95% CI 0.69-2.14), 1.33 (95% CI 1.02-1.73), and 1.58 (95% CI 1.04-2.42), respectively. The corresponding adjusted HRs of reduced early RFS were 0.85 (95% CI 0.46-1.57), 1.34 (95% CI 1.01-1.8), and 1.57 (95% CI 1.03-2.39), respectively. The adjusted HRs of reduced early extrahepatic RFS were 1.89 (95% CI 0.83-4.3) in patients with tumors measuring ≥2 and <5 cm and 2.33 (95% CI 0.98-5.54) in those with tumors measuring ≥5 cm.
CONCLUSIONS: Por HCC measuring ≥2 cm was associated with early recurrence. Hence, it had negative effects on OS. After surgery, patients with Por HCC measuring ≥5 cm should be cautiously monitored for early extrahepatic recurrence. These findings will help physicians devise treatment strategies for patients with HCC.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Hepatocellular carcinoma; Prognosis; Tumor differentiation; Tumor size

Year:  2021        PMID: 34721508      PMCID: PMC8527909          DOI: 10.1159/000517992

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  30 in total

1.  Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma.

Authors:  Akinobu Taketomi; Takeo Toshima; Dai Kitagawa; Takashi Motomura; Kazuki Takeishi; Yohei Mano; Hiroto Kayashima; Keishi Sugimachi; Shinichi Aishima; Yoichi Yamashita; Toru Ikegami; Tomonobu Gion; Hideaki Uchiyama; Yuji Soejima; Takashi Maeda; Ken Shirabe; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2010-04-22       Impact factor: 5.344

Review 2.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

3.  Predictors of intrahepatic multiple recurrences after curative hepatectomy for hepatocellular carcinoma.

Authors:  Kazuki Takeishi; Takashi Maeda; Eiji Tsujita; Yo-Ichi Yamashita; Noboru Harada; Shinji Itoh; Norifumi Harimoto; Toru Ikegami; Tomoharu Yoshizumi; Ken Shirabe; Yoshihiko Maehara
Journal:  Anticancer Res       Date:  2015-05       Impact factor: 2.480

4.  Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis.

Authors:  Michael D Kluger; Juan A Salceda; Alexis Laurent; Claude Tayar; Christophe Duvoux; Thomas Decaens; Alain Luciani; Jeanne Tran Van Nhieu; Daniel Azoulay; Daniel Cherqui
Journal:  J Hepatol       Date:  2014-12-18       Impact factor: 25.083

5.  Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.

Authors:  Ke-Zhu Hou; Zhi-Qiang Fu; Hua Gong
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

6.  Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma.

Authors:  Chetana Lim; Yoshihiro Mise; Yoshihiro Sakamoto; Satoshi Yamamoto; Junichi Shindoh; Takeaki Ishizawa; Taku Aoki; Kiyoshi Hasegawa; Yasuhiko Sugawara; Masatoshi Makuuchi; Norihiro Kokudo
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

7.  Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors.

Authors:  Junichi Shindoh; Andreas Andreou; Thomas A Aloia; Giuseppe Zimmitti; Gregory Y Lauwers; Alexis Laurent; David M Nagorney; Jacques Belghiti; Daniel Cherqui; Ronnie Tung-Ping Poon; Norihiro Kokudo; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2012-11-21       Impact factor: 5.344

Review 8.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

Review 9.  The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan.

Authors: 
Journal:  Jpn J Surg       Date:  1989-01

Review 10.  Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.

Authors:  Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2019-02-21       Impact factor: 5.742

View more
  4 in total

1.  Integrative Analysis Identifies Cell-Type-Specific Genes Within Tumor Microenvironment as Prognostic Indicators in Hepatocellular Carcinoma.

Authors:  Zi-Li Huang; Bin Xu; Ting-Ting Li; Yong-Hua Xu; Xin-Yu Huang; Xiu-Yan Huang
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

2.  Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data.

Authors:  Jie Fu; Xiaohua Lei
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

3.  Cancer cells produce liver metastasis via gap formation in sinusoidal endothelial cells through proinflammatory paracrine mechanisms.

Authors:  Truong Huu Hoang; Misako Sato-Matsubara; Hideto Yuasa; Tsutomu Matsubara; Le Thi Thanh Thuy; Hiroko Ikenaga; Dong Minh Phuong; Ngo Vinh Hanh; Vu Ngoc Hieu; Dinh Viet Hoang; Hoang Hai; Yoshinori Okina; Masaru Enomoto; Akihiro Tamori; Atsuko Daikoku; Hayato Urushima; Kazuo Ikeda; Ninh Quoc Dat; Yutaka Yasui; Hiroji Shinkawa; Shoji Kubo; Ryota Yamagishi; Naoko Ohtani; Katsutoshi Yoshizato; Jordi Gracia-Sancho; Norifumi Kawada
Journal:  Sci Adv       Date:  2022-09-28       Impact factor: 14.957

4.  Accurate prediction of microvascular invasion occurrence and effective prognostic estimation for patients with hepatocellular carcinoma after radical surgical treatment.

Authors:  Yuling Xiong; Peng Cao; Xiaohua Lei; Weiping Tang; Chengming Ding; Shuo Qi; Guodong Chen
Journal:  World J Surg Oncol       Date:  2022-09-30       Impact factor: 3.253

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.